Immunome, Inc. (IMNM)

Immunome Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	98.78	20.42	49.33	39.87	2.64
Short-Term Investments	39.46	0	0	0	0
Cash & Cash Equivalents	138.24	20.42	49.33	39.87	2.64
Cash Growth	576.89%	-58.60%	23.74%	1408.36%	55.29%
Other Current Assets	6.46	2.23	7.31	3.03	0.48
Total Current Assets	144.7	22.65	56.64	42.89	3.12
Property, Plant & Equipment	3.64	0.97	0.86	1.53	1.7
Other Long-Term Assets	0.2	0.43	0.43	0.1	0.24
Total Long-Term Assets	3.84	1.4	1.29	1.63	1.94
Total Assets	148.54	24.05	57.93	44.53	5.06
Accounts Payable	3.31	2.4	3.08	1.19	0.55
Deferred Revenue	15.98	0	0	0	0
Current Debt	0	0	0	0.48	0.45
Other Current Liabilities	2.54	4.93	6.65	1.37	0.67
Total Current Liabilities	21.83	7.33	9.73	3.04	1.67
Long-Term Debt	1.34	0	0	0.13	0.11
Other Long-Term Liabilities	5.49	0.06	0.01	0.01	0.02
Total Long-Term Liabilities	6.83	0.06	0.01	0.14	0.13
Total Liabilities	28.66	7.39	9.74	3.18	1.8
Total Debt	1.34	0	0	0.61	0.56
Debt Growth	-	-	-	8.69%	-52.04%
Retained Earnings	-222.81	-116	-79.11	-54.39	-36.56
Comprehensive Income	0.02	0	0	0	0
Shareholders' Equity	119.88	16.65	48.19	41.35	-35.63
Net Cash / Debt	136.9	20.42	49.33	39.25	2.08
Net Cash / Debt Growth	570.33%	-58.60%	25.67%	1788.07%	295.25%
Net Cash Per Share	6.90	1.68	4.28	11.58	1.90
Working Capital	122.87	15.32	46.91	39.86	1.46
Book Value Per Share	6.04	1.37	4.18	12.20	-32.57

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).